In addition to chemotherapy, targeted therapies have been approved for treatment of locally advanced and metastatic gastric cancer. The therapeutic benefit is significant but more durable responses and improvement of survival should be achieved. Therefore, the identification of new targets and new approaches for clinical treatment are of paramount importance. In this review, we searched the literature for down-regulated microRNAs which interfere with druggable targets and exhibit efficacy in preclinical in vivo efficacy models. As druggable targets, we selected transmembrane receptors, secreted factors and enzymes. We identified 38 microRNAs corresponding to the criteria as outlined. A total of 13 miRs target transmembrane receptors, nine inhibit secreted proteins and 16 attenuate enzymes. These microRNAs are targets for reconstitution therapy of gastric cancer. Further target validation experiments are mandatory for all of the identified microRNAs.

中文翻译：

---

胃癌：在临床前体内模型中鉴定抑制药物靶点和介导功效的 microRNA。

除化疗外，靶向治疗已被批准用于治疗局部晚期和转移性胃癌。治疗益处是显着的，但应该实现更持久的反应和生存率的改善。因此，确定临床治疗的新靶点和新方法至关重要。在这篇综述中，我们搜索了文献，寻找干扰药物靶点并在临床前体内功效模型中表现出功效的下调 microRNA。作为药物靶点，我们选择了跨膜受体、分泌因子和酶。我们确定了与概述的标准相对应的 38 个 microRNA。共有 13 个 miR 靶向跨膜受体，9 个抑制分泌蛋白，16 个减弱酶。这些微小RNA是胃癌重建治疗的靶点。所有已识别的 microRNA 都必须进行进一步的目标验证实验。